Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne

/PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC40 for moderate to...

Related Keywords

China ,Shaoxing ,Zhejiang ,Hong Kong ,Huashan ,Henan ,Hangzhou ,Chinese ,Leihong Xiang ,Jinzij Wu ,Market Research ,Fudan University ,Dermatological Department ,Hong Kong Stock Exchange ,Institute Of Dermatology ,Dermatology Division Of Chinese Medical Doctor Association ,Ascletis Pharma Inc ,Ascletis Pharma ,Global Assessment ,Allied Market Research ,Huashan Hospital ,Dermatology Division ,Chinese Medical Doctor ,Hepatitisb Virus ,Primary Biliary Cholangitis ,